IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3000
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$238M
Marc Voigt
Immutep Limited engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$IMMP IMMUTEP Ltd | 44 | 25 | 15 | 79 | - | - | -171.1% | -156.5% | 99.3% | -1292.2% | -1220.3% | 29.0% | 0.0% | 0.0x | $238M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
IMMUTEP Ltd (IMMP) receives a "Reduce" rating with a composite score of 43.8/100. It ranks #3000 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Marc Voigt
Chief Executive Officer
25
63
57
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for IMMP
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Conservative, efficient capex — capital discipline signals management quality
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for IMMP.
View All RatingsImproving capital utilization rates confirmed
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 25 | 3 | +22ALPHA |
| MOMENTUM | 79 | 83 | -4NEUTRAL |
| VALUATION | 15 | 3 | +12ALPHA |
| INVESTMENT | 63 | 98 | -35DRAG |
| STABILITY | 57 | 45 | +12ALPHA |
| SHORT INT | 25 | 10 | +15ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -171.1% (sector -2.5%)
GM 99% vs sector 43%, OM -1292% vs sector 1%
Capital turnover N/A, R&D intensity 1219.8%
Rev growth 29%, 8yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
IMMUTEP Ltd receives a Reduce rating from our analysis, with a composite score of 43.8/100 and 2 out of 5 stars, ranking #3000 out of 7,333 stocks. IMMP's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
IMMP's quality score of 25/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -171.1% (sector avg: -2.5%), gross margins of 99.3% (sector avg: 42.5%), net margins of -1220.3% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
IMMP registers a value score of just 15/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 4.35x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
IMMP shows a solid investment score of 63/100, reflecting measured but productive capital allocation. Key growth metrics include revenue growth of 29.0% vs. a sector average of 5.9% and a return on assets of -156.5% (sector: -0.1%). This suggests the company is investing at an appropriate level to sustain growth without overextending its balance sheet.
IMMP shows strong momentum characteristics with a score of 79/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at 29.0% year-over-year, while a beta of 0.72 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
With a stability score of 57/100, IMMP exhibits average financial resilience. Key stability metrics include a beta of 0.72 and a debt-to-equity ratio of 0.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
IMMUTEP Ltd's short interest score of 25/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include micro-cap liquidity risk. At $238M (micro-cap), IMMP carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
IMMUTEP Ltd is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3000 of 7,333 overall (59th percentile). Key comparisons include ROE of -171.1% trailing the -2.5% sector median and operating margins of -1292.2% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While IMMP currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (15) would have the largest impact on the composite score.
ROE 6798% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 134% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 100273% BELOW SECTOR MEDIAN
AUDIT DATA AS OF JUN 30, 2025 (Q1 FY2025)
We rate IMMUTEP Ltd (IMMP) as a Reduce with a composite score of 43.8/100 at a current price of $2.79. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in momentum (79th percentile) and investment (63th percentile), which together account for the majority of the composite score. Offsetting weakness in value (15th percentile) and quality (25th percentile) tempers our overall conviction. We assign a Narrow Moat rating (46/100), Medium uncertainty, and Poor capital allocation.
Key items to watch: sustainability of the current growth rate; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
IMMUTEP Ltd holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 43.8/100 places it at rank #3000 in our full 7,333-stock universe. At $238M in market capitalization, IMMUTEP Ltd is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
The near-term outlook is constructive, with revenue growing at 29% and momentum in the 79th percentile confirming positive market sentiment and institutional accumulation. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy. Investment factor at the 63th percentile indicates the company is reinvesting effectively to sustain this trajectory.
The margin cascade tells an important story: gross margins of 99% (+56.8pp vs sector) narrow to operating margins of -1292% (-1293.5pp vs sector) and net margins of -1220.3%, yielding a gross-to-net conversion rate of -1229%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $2.79, IMMUTEP Ltd is trading at a premium to fundamental value. Our value factor score of 15/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 4.3x, P/S of 31.0x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 99% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 29% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A conservative balance sheet (0% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
Positive momentum (79th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
The Reduce rating (composite 43.8/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
We assign a Medium uncertainty rating to IMMUTEP Ltd. The stock presents a balanced risk profile: current negative profitability (net margin -1220.3%) and weak quality scores (25th percentile). While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: current negative profitability (net margin -1220.3%); weak quality scores (25th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 57th percentile and quality factor at the 25th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 99% provide a buffer against cost pressures; conservative leverage (0% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate IMMUTEP Ltd's capital allocation as Poor. Key concerns include low returns on equity (-171.1%), negative profitability, weak asset returns (ROA -156.5%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — IMMUTEP Ltd significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, IMMUTEP Ltd receives a Reduce rating with a composite score of 43.8/100 (rank #3000 of 7,333). Our quantitative framework assigns a Narrow Moat (46/100, trend: stable), Medium uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 48/100.
Our analysis does not support a constructive view on IMMUTEP Ltd at this time. The combination of the current quantitative profile, medium uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign IMMUTEP Ltd a Narrow Moat rating with a composite moat score of 46/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that IMMUTEP Ltd can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being reinvestment efficiency at 14/20.
The strongest moat sources are reinvestment efficiency (14/20) and margin superiority (12.9/20). Capital turnover N/A, R&D intensity 1219.8%. GM 99% vs sector 43%, OM -1292% vs sector 1%. These pillars form the core of IMMUTEP Ltd's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (1.4/20) and financial resilience (7/20). ROE proxy -171.1% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect IMMUTEP Ltd's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 99% providing a solid profitability foundation, robust top-line growth of 29% expanding the revenue base. The margin cascade from 99% gross to -1292% operating to -1220.3% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 25th percentile.
The margin profile shows gross margins of 99%, operating margins of -1292%, net margins of -1220.3%. Return metrics include ROE of -171.1% and ROA of -156.5%. Relative to the Manufacturing sector, gross margins are 56.8 percentage points above the sector median of 43%, and ROE of -171.1% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 0%, revenue growth of 29%. The sector median D/E is 0%, putting IMMUTEP Ltd in a relatively stronger balance sheet position. Overall balance sheet health is adequate for the current business environment.
Thin net margins of -1220.3% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Below-average quality (25th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Above 50MA
37.18%
Net New Highs
+51081

Four ASX shares are rising despite the broader market selloff: 29Metals, Immutep, Insignia, and Perenti. The reasons include positive drilling results, regulatory feedback, improved financial performance, and strong cash flow expectations.
We recently published 7 Best ASX Stocks to Buy Right Now. Immutep Limited (NASDAQ:IMMP) is one of the best ASX stocks. Immutep Limited (NASDAQ:IMMP) is a biotechnology company developing therapies for cancer and autoimmune diseases. The firm’s shares underwent notable traction earlier this week after Indian firm Dr. Reddy’s Laboratories Ltd.’s subsidiary entered into an […]
Immutep Limited (NASDAQ:IMMP) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. In mid-November, Immutep Limited (NASDAQ:IMMP) reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. The firm revealed that a Phase 2 study of efti in combination with radiotherapy and Merck’s Keytruda showed significant […]

Immutep Ltd (ASX: IMM) is surging after receiving positive feedback from the FDA for its planned Phase 3 trial of its eftilagimod alfa compound in combination with Merck & Co's Keytruda for treating non-small cell lung cancer. This is a critical milestone for the company.

Immutep announced positive results from cohort B of the late-stage TACTI-003 study, evaluating the combination of its pipeline candidate eftilagimod alfa and Merck's Keytruda as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma. The combination therapy showed promising efficacy and safety data, strengthening the evidence that efti's novel mechanism of action significantly boosts the immune system.